RT001 – Novel Topical Formulation of Botulinum Toxin
RT001 (Botulinum Toxin Type A) Topical Gel for the Treatment of Lateral Canthal Lines
RT001, our lead product candidate, is an investigational product that is a topical gel formulation of botulinum toxin type A in a proprietary single-use administration apparatus. RT001 is applied to the skin and uses our proprietary TransMTS® peptide technology to enable delivery of botulinum toxin across the skin, eliminating the need for injections. Our initial focus is to develop and commercialize RT001 for indications where topical application provides a meaningful advantage over injectable administration. RT001 is currently in a Phase 3 clinical development program in the United States for the treatment of crow’s feet lines.
Crow’s Feet Lines — Our Lead Indication for RT001
The first indication we are pursuing for RT001 is for crow’s feet lines, the skin wrinkles in the outer corner of the eye area, which are commonly caused by aging. Consumers in general, and women in particular, believe that the eye area is the first place where they notice the signs of aging1. Consumers also believe that the perception of aging is affected by the quality of the skin. A large segment of the anti-aging topical cosmeceutical market is targeted towards improvement in skin texture and luminosity of the skin in the eye area.
1 American Society for Dermatologic Surgery (ASDS) Consumer Survey on Cosmetic Dermatologic Procedures, 2013
Expanding the Market
Today’s culture places significant value on physical appearance, leading to widespread adoption of anti-aging and aesthetic treatments. The aesthetic market has grown dramatically in the United States, according to American Society for Aesthetic Plastic Surgery annual statistics. A strong consumer preference for non-surgical options and the increasing availability of effective alternatives has prompted adoption of non-surgical aesthetic procedures by a broader patient population. These trends have made non-surgical procedures the primary driver of growth in the aesthetic medicine market, accounting for 83% of the total number of procedures performed in 20121. Injectable botulinum toxin treatments are the single largest cosmetic procedure in the United States and the rest of the world.
Aesthetics/Dermatology is the largest single addressable target market for botulinum toxins. The botulinum toxin market could expand further with the introduction of a topical formulation such as RT001. Market research2 suggests some current barriers to injectable botulinum toxin use include fear of frozen face and needle aversion, two issues that may be overcome with a topical botulinum toxin. According to the American Society for Dermatologic Surgery’s Consumer Survey on Cosmetic Dermatologic Procedures 2013, more women are bothered by the wrinkles around their eyes (crow’s feet) than any other facial wrinkles, with 63%3 of women bothered by their crow’s feet, the target indication in clinical trials for RT001.
1 GlobalData, “Facial Aesthetics (Botulinum Toxin, Dermal Fillers) – Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2018, April 2012
2 Revance Quantitative Consumer Primary Market Research, 2009 and 2012
3 American Society for Dermatologic Surgery (ASDS) Consumer Survey on Cosmetic Dermatologic Procedures, 2013